Lineage Cell Therapeutics... (LCTX)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.71 |
Market Cap | 155.86M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.1 |
PE Ratio (ttm) | -7.07 |
Forward PE | n/a |
Analyst | Buy |
Ask | 0.71 |
Volume | 1,027,239 |
Avg. Volume (20D) | 2,691,688 |
Open | 0.71 |
Previous Close | 0.71 |
Day's Range | 0.69 - 0.73 |
52-Week Range | 0.48 - 1.61 |
Beta | undefined |
About LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa mul...
Analyst Forecast
According to 4 analyst ratings, the average rating for LCTX stock is "Buy." The 12-month stock price forecast is $3.5, which is an increase of 394.98% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription